Giorgio Gandaglia

Active 2012–2026

213
Papers
19,057
Citations
73
h-index
182
i10-index

Citations

Citations per year for Giorgio Gandaglia2005: 1 citations2012: 2 citations2013: 8 citations2014: 22 citations2015: 38 citations2016: 69 citations2017: 65 citations2018: 40 citations2019: 272 citations2020: 500 citations2021: 637 citations2022: 679 citations2023: 580 citations2024: 1,108 citations2025: 602 citations2026: 22 citations2006–2011: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,178 citing papers, 14.9% of this breakdownItaly: 813 citing papers, 10.3% of this breakdownChina: 663 citing papers, 8.4% of this breakdownGermany: 596 citing papers, 7.5% of this breakdownUnited Kingdom: 441 citing papers, 5.6% of this breakdownNetherlands: 373 citing papers, 4.7% of this breakdownCanada: 341 citing papers, 4.3% of this breakdownFrance: 312 citing papers, 4% of this breakdownSwitzerland: 276 citing papers, 3.5% of this breakdownAustria: 255 citing papers, 3.2% of this breakdownSpain: 248 citing papers, 3.1% of this breakdownBelgium: 222 citing papers, 2.8% of this breakdown
0%14.9%Other 27.7%

Fields

  • Medicine87%
  • Biochemistry, Genetics and Molecular Biology7.1%
  • Computer Science1.3%
  • Engineering1.1%
  • Immunology and Microbiology0.8%
  • Health Professions0.4%
  • Other2.3%

Topics

  • Prostate Cancer Diagnosis and Treatment18.6%
  • Prostate Cancer Treatment and Research17.2%
  • Bladder and Urothelial Cancer Treatments4.9%
  • Advanced Radiotherapy Techniques2.8%
  • Radiopharmaceutical Chemistry and Applications2.8%
  • Urinary and Genital Oncology Studies2.7%
  • Other51%

Coauthors

All papers

Open in search
  1. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 2,814

  2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Derya Tilki - European Urology 2024 cited by 1,087

  3. Epidemiology and Prevention of Prostate Cancer

    Authors: , , , , , , , , - European Urology Oncology 2021 cited by 609

  4. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 1,126

  5. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip Cornford - European Urology 2024 cited by 313

  6. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies

    Authors: , , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 315

  7. A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease

    Authors: , , , , , , - European Urology 2013 cited by 528

  8. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard

    Authors: , , , , , , , , , , , , , - European Urology Oncology 2021 cited by 119

  9. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2019 cited by 320

  10. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , , , , , , , - European Urology 2022 cited by 107

  11. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , , , , , - European Urology Oncology 2020 cited by 179

  12. Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis

    Authors: , , , , , , , , , , , - The Prostate 2013 cited by 564

  13. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies

    Authors: , , , , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 83

  14. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer

    Authors: , , , , , , , , - European Urology 2014 cited by 336

  15. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tobias Gross, Jeremy Grummet, Ann Henry, Alexandre Ingels, Jacques Irani, Michael Lardas, Matthew Liew, Daniel W. Lin, Lisa Moris, Muhammad Imran Omar, Karl H. Pang, Catherine Paterson, Raphaële Renard‐Penna, María J. Ribal, Monique J. Roobol, Morgan Rouprêt, Olivier Rouvière, Gemma Sancho, Jonathan Richenberg, Ivo G. Schoots, J.P. Michiel Sedelaar, Phillip D. Stricker, Derya Tilki, Susanne Vahr Lauridsen, Roderick C.N. van den Bergh, Thomas Van den Broeck, Theodorus van der Kwast, Henk G. van der Poel, Geert J.L.H. van Leenders, Murali Varma, Philippe D. Violette, Christopher J.D. Wallis, Thomas Wiegel, Karen Wilkinson, Fabio Zattoni, James Michael Olu N'Dow, Hendrik Van Poppel, Philip Cornford, Nicolas Mottet - European Urology 2019 cited by 239

  16. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2022 cited by 94

  17. Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy

    Authors: , , , , , , , , , , , , - European Journal of Radiology 2023 cited by 59

  18. Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies

    Authors: , , , , , , , , , , , , - Prostate Cancer and Prostatic Diseases 2019 cited by 36

  19. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 178

  20. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fábio Ynoe de Moraes, Alejandro Berlín, Antonio Finelli, Nicola Fossati, Giorgio Gandaglia, Alberto Briganti, Peter R. Carroll, R. Jeffrey Karnes, Michael W. Kattan, Matthew J. Schipper, Daniel E. Spratt - JAMA Oncology 2020 cited by 91

  21. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer

    Authors: , , , , , , , , , , , , , , - European Urology 2017 cited by 238

  22. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Van den Broeck, Theodorus van der Kwast, Henk G. van der Poel, Thomas Wiegel, Cathy Yuhong Yuan, Philip Cornford, Nicolas Mottet, Thomas Lam - European Urology 2021 cited by 102

  23. Magnetic Resonance Imaging in Prostate Cancer Screening

    Authors: , , , , , , , , , , , , , , , , , - JAMA Oncology 2024 cited by 80

  24. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2021 cited by 68